

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicants: Alexander Gad and Dora Lis			
				Filing Date Herewith		Group Art Unit	

  

U.S. PATENT DOCUMENTS											
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate				
		3 8 4 9 5 5 0	11/19/74	Teitelbaum, et al.							
		3 9 9 1 2 1 0	11/09/76	Shea							
		4 3 3 9 4 3 1	7/13/82	Gaffar							
		5 2 0 4 0 9 9	4/20/93	Barbier, et al.							
		5 5 5 4 3 7 2	9/10/96	Hunter et al.							
		5 5 8 3 0 3 1	12/10/96	Stern							
		5 5 9 1 6 2 9	1/7/97	Rodriguez, et al.							
		5 6 2 3 0 5 2	4/22/97	McLean et al.							
		5 6 2 7 2 0 6	5/6/97	Hupe, et al.							
		5 6 6 8 1 1 7	9/16/97	Shapiro, et al.							
		5 7 1 9 2 9 6	2/17/98	Acton, et al.							

  

FOREIGN PATENT DOCUMENTS											
		Document Number	Date	Country	Class	Subclass	Translation				
							Yes	No			
	WO	8 8 0 2 1 3 9	12/29/88	US							
	WO	9 2 0 2 5 4 3	2/20/92	Europe							
	WO	9 4 0 3 4 8 4	2/17/94	US							
	WO	9 4 2 6 7 7 4	11/24/94	US							
	WO	9 5 2 6 9 8 0	10/12/95	US							
	WO	9 5 3 1 9 9 7	11/30/95	US							

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <i>J. Neurol. Sci.</i> , 1977, <u>31</u> , 433-438
	Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", <i>Eur. J. Immunol.</i> , 1993, <u>23</u> , 17-25;
	Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", <i>Immunol. Letters</i> , 1997, <u>58</u> , 79-87;
	Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <i>Ann. Neurol.</i> , 1979, <u>6</u> , 469-473
	Amon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <i>Israel J. Med. Sci.</i> , 1972, <u>8</u> , 1759-1760;

  

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

  

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)						Applicants: Alexander Gad and Dora Lis  Filing Date Herewith			
<b>U.S. PATENT DOCUMENTS</b>									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
		5 7 3 4 0 2 3	3/31/98	Bishwajit et al.					
		5 8 0 0 8 0 8	9/1/98	Konfino, et al.					
		5 8 5 8 9 6 4	1/12/99	Aharoni, et al.					
		5 8 8 6 1 5 6	3/23/99	McLean et al.					
		5 9 5 8 9 7 2	9/28/99	Hupe, et al.					
		5 9 8 1 5 8 9	11/9/99	Konfino, et al.					
		6 0 4 8 8 9 8	4/11/00	Konfino, et al.					
		6 0 5 4 4 3 0	4/25/00	Konfino, et al.					
		6 2 1 4 7 9 1	4/10/01	Arnon, et al.					
		6 3 4 2 4 7 6	1/29/02	Konfino, et al.					
		6 3 6 2 1 6 1	3/26/02	Konfino, et al.					
<b>FOREIGN PATENT DOCUMENTS</b>									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
	WO	9 5 3 1 9 9 0	11/30/95	US					
	WO	9 5 3 3 4 7 5	12/14/95	Europe					
	WO	9 8 3 0 2 2 7	7/16/98	US					
	WO	0 0 0 5 2 4 9	2/3/00	US					
	WO	0 0 0 5 2 5 0	2/3/00	US					
	WO	0 0 1 8 7 9 4	4/6/00	US					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
	Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, <u>28</u> , 336 (Abstract);								
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107;								
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;								
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, <u>55</u> , 5-30;								
	Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in <u>A Multidisciplinary Approach to Myelin Disease</u> (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250								
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>						
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Form PTO-1449		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known						
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)						Applicants: Alexander Gad and Dora Lis								
						Filing Date Herewith		Group Art Unit						
<b>U.S. PATENT DOCUMENTS</b>														
<b>Examiner Initial</b>		<b>Document Number</b>							<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>	
		6	5	1	4	9	3	8	2/4/03	Gad et al.				
		6	6	2	0	8	4	7	9/16/03	Konfino, et al.				
		20	01	00	55	56	8	A1	12/27/01	Gilbert, et al.				
		20	02	00	37	84	8	A1	03/28/02	Eisenbach-Schwartz et al.				
		20	02	01	07	38	8	A1	08/08/02	Vandembark				
		20	02	01	15	10	3	A1	8/22/02	Gad, et al.				
		20	03	00	04	09	9	A1	01/02/03	Eisenbach-Schwartz et al.				
		09	3	5	9	0	9	9	7/22/99	Strominger, et al.				
		09	4	8	7	7	9	3	1/20/00					
		09	6	2	0	2	1	6	7/20/02					
		09	7	6	5	3	0	1						
<b>FOREIGN PATENT DOCUMENTS</b>														
		<b>Document Number</b>							<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
													<b>Yes</b>	<b>No</b>
		WO	0	0	2	0	0	1	0	4/13/00	US			
		WO	0	0	2	7	4	1	7	5/18/00	US			
		WO	0	1	5	2	8	7	8	7/26/01	US			
		WO	0	1	6	0	3	9	2	8/23/01	US			
		WO	0	1	9	3	8	9	3	12/3/01	US			
		WO	0	1	9	3	8	2	8	12/13/01	US			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
		Pending claims of U.S. Serial No. 09/816,989 (Gad et al.)(Item 28)., U.S. Patent Publication No. 20020115103 A1, for the Examiner's convenience												
		Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", <u>Israel J. Med. Sci.</u> , 1989, <u>25</u> , 686-689;												
		Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, <u>29</u> , 175-181;												
		Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>100</u> , 2-7;												
		Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, <u>1</u> , 65-70;												
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>												
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

[illegible][illegible]

	Babu et al., "Reevaluation of response patterns of nonresponder mice to GLPhe polymers", <u>Immunogen.</u> , 1983, 18(1): 97-100 (Abstract)
	Babu et al., "Ir gene control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", <u>J. Immunogenet.</u> , 1984, 11(3-4): 251-254
	Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, 14(2), 146-153
	Baumhefner, et al., "Copolymer I as Therapy for Multiple Sclerosis: The Cons", <u>Neurol.</u> , 1988, 38(Suppl. 2), 69-71
	Baxevanis et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu <sup>40</sup> Ala <sup>60</sup> ) and Poly (Glu <sup>51</sup> Lys <sup>34</sup> Tyr <sup>15</sup> ): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", <u>Immunogenetics</u> , 1980, 11: 617-628

**DATE CONSIDERED**

\***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis		Filing Date Herewith	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in <u>Handbook of Multiple Sclerosis</u> (S.D. Cook Marcel Rekker, ed., 1990) 469-480						
		Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", <u>Neurol.</u> , 1991, <u>41</u> , 533-539						
		Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in <u>Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives</u> (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198						
		Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, <u>436</u> , 498-499						
		Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", <u>Neurol.</u> , 1985, <u>35</u> , 1754-1759						
		Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", <u>Neurol.</u> , 1985, <u>35</u> (Suppl. 1), 170 (Abstract)						
		Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", <u>Neurol.</u> , 1986, <u>36</u> , 92-94						
		Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", <u>Neurol.</u> , 1991, <u>41</u> , 1317-1319						
		Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", <u>Drug Therapy</u> , 1990, 31-32, 37-39, 42-43						
		Cazzato et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit'a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina, October 1999, <u>90</u> (10): 538-544 (Abstract)						
		Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991)						
		Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993						
EXAMINER		DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis		Filing Date Herewith	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Cohen, "Fundamental Immunology", <u>Systemic Autoimmunity</u> , 4 <sup>th</sup> Ed., 1999, 1083						
		The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6						
		Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News &amp; Perspectives</u> , 1994, 272(18), 1393						
		Deeb et al., "Comparision of Freund's and Ribi adjuvants for inducing antibodies to the synthetic antigen (TG)-AL in rabbits", <u>J. Immunol. Methods</u> , 1992, 152(1): 105-113 (Abstract)						
		De Kruffy et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", <u>Eur. J. Immunol.</u> , 1987, 17 (8): 1115-1120 (Abstract)						
		Dorling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u> , 1994, 6, 765-769						
		Durelli, "Immunotherapeutics of Multiple Sclerosis", <u>Istituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino</u> , 467-475;						
		Falo et al., "Analysis of antigen presentation by metabolically inactive accessory cells and their isolated membranes", <u>Proc. Natl. Acad. Sci. USA</u> , 1985, 82(19): 6647-6651 (Abstract)						
		Ferrara, et al., "Graft-Versus-Host Disease", <u>New Eng. J. Med.</u> , 1991, 324, 667-674						
		Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, 18, 77-84						
		Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , 1994						
		Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", <u>Proc. Natl. Acad. Sci. USA</u> , 1994, 91, 4872-4876						
EXAMINER			DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis			
					Filing Date Herewith		Group Art Unit	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
		Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u> , 1994, 21-22 (Abstract)						
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in <u>Neurochem Mtg.</u> , August 14-19, 1994						
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", <u>J. Neurochem.</u> , 1994, 63(Suppl. I), 561						
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , Rehovot, Israel, 1994						
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", <u>Israeli Immunol. Soc.</u> , May 3-4, 1994 (Abstract)						
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", <u>Cell. Immunol.</u> , 1995, 163, 229-236						
		Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", <u>J. Immunol.</u> , 1998, 160, 4386-4397						
		Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-Reactive T Cell Clones", <u>Proc. Natl. Acad. Sci.</u> , 1998, 95, 12528-12531						
		Fridkis-Hareli et al., "Binding of random copolymers of three amino acids to class II MHC molecules", <u>Intl. Immunol.</u> , 1999, 11(5): 635-641						
		Fridkis-Hareli et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, <u>Human Immunology</u> , 2000, 61(7): 640-650 (Abstract)						
		Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", <u>Int. Immunol.</u> , 1990, 2(8), 713-718						
		Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract)						
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known				
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicants:</b> Alexander Gad and Dora Lis		Filing Date Herewith		Group Art Unit		
<b>U.S. PATENT DOCUMENTS</b>											
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate				
<b>FOREIGN PATENT DOCUMENTS</b>											
		Document Number	Date	Country	Class	Subclass	Translation				
							Yes		No		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>											
		Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, 12(6): 704-711									
		Henry, Celia M., "Special Delivery", <u>Chem. and Eng. News</u> , Sept. 18, 2000, 49-54									
		Herzenberg et al., "Lack of immune response gene control for induction of epitope-specific suppression by TGAL antigen", <u>Nature</u> , 1982, 295: 329-331 (Abstract)									
		Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", <u>Neurol.</u> , 1994, 7, 250-254									
		Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in <u>Congress for Advances in the Understanding and Treatment of Multiple Sclerosis</u> , Boston (USA), Oct. 28-29, 1992									
		Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", <u>Ann. Neurol.</u> , 1994, 36(Suppl.), 115-117									
		Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", <u>Chemical Abstracts</u> , 1996, 125, 291993b									
		Ju et al., "Idiotypic analysis of antibodies against the terpolymer L-glutamic acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT idio type following immunization with various synthetic polymers containing glutamic acid and tyrosine", <u>Eur. J. Immunol.</u> , 1979, 9(7): 553-560 (Abstract)									
		Kay, et al., "The Mechanism of Action of FK 506", <u>Transplantation Proceedings</u> , 1990, 22(1, Suppl. 1), 96-99									
		Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, 42, 267-274									
		Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, 102, 309-320									
		Kepsutlu et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3): 27-235 (Abstract)									
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>								
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis		Filing Date Herewith	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
		Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Assoc.</u> , December 19-20, 1994, Herzliya (Israel), 17						
		Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH <sub>2</sub> -Terminal Including Proline as a Stop Signal for Trimming", <u>J. Immunol.</u> , 1993, 151: 4732-4742						
		Lai et al., "Complementation of Class II A alleles in the immune response to (GluLysTyr) polymers", <u>Exp. Clin. Immunogenet.</u> , 1986, 3(1): 38-48 (Abstract)						
		Lai et al., "Monoclonal T cell responses to two epitopes on a single immunogen controlled by two distinct genes", <u>J. Immunol.</u> , 1986, 136(10): 3799-3804 (Abstract)						
		Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, 123, 2156-2160 (Abstract)						
		Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, 15, 868-869 (Abstract)						
		Lee, et al., "Peptide and Protein Drug Delivery" in <u>Advances in Parenteral Sciences</u> (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695						
		Li et al., "Glatiramer acetate blocks the activation of THP-1 cells by interferon- $\gamma$ ", <u>Eur. J. Pharmacol.</u> , 1998, 342: 303-310						
		Lisak, et al., "Effect of Treatment with Copolymer I (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u> , 1983, 62, 281-293						
		Matsunaga et al., "Complementation of Class II A alleles in the immune response to (Glu-Lys-Tyr) polymers", <u>Yokohama Med. Bull.</u> , 1988, 39(1-2): 9-19 (Abstract)						
		Maurer et al., "Interpretations of immune responses of mice to poly(Glu60Lys40), its modified derivatives, and the terpolymers poly (Glu55Lys37Leu8) and poly (Glu56Lys37Ser7)", <u>Clin. Immunol. Immunopathol.</u> , 1980, 15(3): 344-356 (Abstract)						
		McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, 46, 137-143						
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>						
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis		Filing Date Herewith	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", <u>J. Neurol.</u> , 1991(Suppl. 1) (Abstract)						
		Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two-year Follow-up", in <u>9<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract)						
		Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in <u>Encycl. Molecular Bio.</u> (Oxford Blackwell Science Ltd, 1994) 602-606						
		Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", <u>Israel J. Med. Sci.</u> , 1992, <u>28</u> , 486 (Abstract)						
		Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract)						
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, <u>44</u> (Suppl. 2), A212						
		Milo, et al., "Additive Effect of Copolymer-1 and Interferon- $\beta$ on the Immune Response to Myelin Basic Protein", <u>Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine</u> , 1994, 22						
		Milo, et al., "Copolymer-1 and Interferon- $\beta$ Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", <u>J. Neuroimmunol.</u> , 1994, <u>54</u> , 183 (Abstract)						
		Milo, et al., "Additive Effects of Copolymer-1 and Interferon $\beta$ -1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, <u>61</u> , 185-193						
		Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", <u>Neurologic Clinics</u> , 1990, <u>8</u> (1), 119-141						
		Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", <u>Am. Family Physician</u> , 1994, <u>50</u> (4), 845-847						
		O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1598-1614						
EXAMINER			DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				<b>Atty. Docket No.</b> 60807-AA-PCT-US/ JPW/ GJG/DJK		<b>Serial No.</b> Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)						<b>Applicants:</b> Alexander Gad and Dora Lis			
						<b>Filing Date</b> Herewith		<b>Group Art Unit</b>	
<b>U.S. PATENT DOCUMENTS</b>									
<b>Examiner Initial</b>		<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>		
<b>FOREIGN PATENT DOCUMENTS</b>									
		<b>Document Number</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>		
							Yes	No	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
		Pender, et al., Internal Med. Journal, 2002, 32: 554-563							
		Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1650-1659							
		Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," <u>Ann. Neurol.</u> , 1999, 46: 253-256							
		Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", <u>J. Immunol.</u> , 1997, 158, 2471-2476							
		Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", <u>J. Neuroimmunol.</u> , 1992, 37, 75-84							
		Reilly, Jr., W.J., "Pharmaceutical Necessities" in <u>The Science and Practice of Pharmacy</u> , Remington 1995, 2, 1380-1416							
		Rolak, "Copolymer-I Therapy for Multiple Sclerosis", <u>Clin. Neuropharmacology</u> , 1987, 10(5), 389-396							
		Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", <u>Ann. Rev. Immunol.</u> , 1991, 9, 527-565							
		Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", <u>Department of Neurological Sciences, University of Rome, La Sapienza</u> 1991, 72 (Abstract)							
		Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", <u>Blood</u> , 1994, 84(8), 2802-2810							
		Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in <u>Am. Soc. Hematology</u> , 37 <sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)							
		Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", <u>J. Immunol.</u> , 1979, 123(1): 272-278 (Abstract)							
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>							
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known				
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicants:</b> Alexander Gad and Dora Lis		Filing Date Herewith		Group Art Unit		
<b>U.S. PATENT DOCUMENTS</b>											
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate				
<b>FOREIGN PATENT DOCUMENTS</b>											
		Document Number	Date	Country	Class	Subclass	Translation				
							Yes		No		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>											
		Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology</u> , vol. 1, <u>First Symposium of Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21									
		Sela, et al., "Suppressive Activity of COP-1 in EAE and its Relevance to Multiple Sclerosis", <u>Bull. Inst. Pasteur</u> , 1990, <u>88</u> , 303-314									
		Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, <u>70/71</u> , 147-155									
		Starzl, <u>Transplantation Proceedings</u> , 1990, <u>22</u> (1, Suppl. 1), 5									
		Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", <u>Ann. Neurol.</u> , 1994, <u>36</u> , 114-115									
		Sykes, "Immunobiology of Transplantation", <u>Faseb J.</u> , 1996, <u>10</u> , 721-730									
		Tarcic et al., "Copolymer I (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, <u>281</u> (14), 16-18 (Abstract)									
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Eur. J. Immunol.</u> , 1971, <u>1</u> , 242-248									
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, <u>7</u> , 630-631 (Abstract)									
		Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, <u>240</u> , 564-566									
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", <u>Eur. J. Immunol.</u> , 1973, <u>3</u> , 273-279									
		Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <u>Israel J. Med. Sci.</u> , 1974, <u>10</u> (9), 1172-1173									
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>								
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											



Form PTO-1449		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>			<b>Atty. Docket No.</b> 60807-AA-PCT-US/ JPW/ GJG/DJK		<b>Serial No.</b> Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicants:</b> Alexander Gad and Dora Lis			
					<b>Filing Date</b> Herewith		<b>Group Art Unit</b>	
<b>U.S. PATENT DOCUMENTS</b>								
<b>Examiner Initial</b>		<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>	
<b>FOREIGN PATENT DOCUMENTS</b>								
		<b>Document Number</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
		Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", <u>Immunol. Today</u> , 1985, 6(4), 141						
		Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity16" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 1994, 91, 437-438						
		Trannoy et al., "Epitope-specific regulation of the T cell repertoire: carrier recognition in association with I-E or I-A does not influence the restriction of hapten-specific T cells", <u>Eur. J. Immunol.</u> , 1985, 15(12): 1215-1221 (Abstract)						
		Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", <u>Transplantation</u> , 1991, 52, 15-20						
		Van Noort, et al., International Review of Cytology, 1996, 178: 127-205						
		Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657						
		Wender, "Copolymer I (COP-1) in the Treatment of Multiple Sclerosis (letter)" <u>Neur. Neurochir. Pol.</u> , 1990, 24, 113						
		Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", <u>Current Opinion in Neurol. and Neurosurgery</u> , 1992, 5, 203-211						
		Webb, et al., "In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1973, 3, 279-286						
		Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Isr. J. Med. Sci.</u> , 1975, 11, 1388 (Abstract)						
		Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <u>Immunochem.</u> , 1976, 13, 333-337						
		Webster's II New Riverside University Dictionary, definition of "preventing", The Riverside Publishing Co., 1984, page 933						
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60807-AA-PCT-US/ JPW/ GJG/DJK		Serial No. Not Yet Known	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: Alexander Gad and Dora Lis		Group Art Unit	
					Filing Date Herewith			
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
		Winer, "COP 1 Therapy for Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 442-444						
		Zisman et al., "Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A--L", <u>Eur. J. Immunol.</u> , 1994, 24(10): 2497-2505 (Abstract)						
		Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Complex molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", <u>Proc. Natl. Acad. Sci. USA</u> , 1991, 88(21): 9732-9742 (Abstract)						
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								